OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSURFree Report) by 135.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 492,477 shares of the medical instruments supplier’s stock after acquiring an additional 283,001 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.64% of OraSure Technologies worth $3,029,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of OSUR. Trexquant Investment LP raised its position in shares of OraSure Technologies by 3.3% during the 3rd quarter. Trexquant Investment LP now owns 64,644 shares of the medical instruments supplier’s stock worth $383,000 after purchasing an additional 2,049 shares during the period. Diversified Trust Co lifted its stake in OraSure Technologies by 17.7% in the fourth quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 2,406 shares during the last quarter. AJOVista LLC acquired a new position in shares of OraSure Technologies during the fourth quarter valued at $39,000. Los Angeles Capital Management LLC grew its position in shares of OraSure Technologies by 2.6% during the first quarter. Los Angeles Capital Management LLC now owns 341,125 shares of the medical instruments supplier’s stock worth $2,098,000 after acquiring an additional 8,523 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of OraSure Technologies in the 4th quarter worth about $113,000. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Trading Down 4.4 %

OSUR stock opened at $4.08 on Wednesday. OraSure Technologies, Inc. has a one year low of $4.07 and a one year high of $8.45. The firm has a 50-day moving average of $4.82 and a two-hundred day moving average of $6.28. The firm has a market capitalization of $301.76 million, a PE ratio of 13.60 and a beta of 0.09.

OraSure Technologies (NASDAQ:OSURGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported $0.04 EPS for the quarter, meeting the consensus estimate of $0.04. OraSure Technologies had a net margin of 7.50% and a return on equity of 7.68%. The business had revenue of $54.10 million during the quarter, compared to the consensus estimate of $52.27 million. During the same quarter in the prior year, the firm earned $0.37 EPS. The firm’s quarterly revenue was down 65.1% on a year-over-year basis. On average, equities research analysts anticipate that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on OSUR. JPMorgan Chase & Co. reduced their target price on shares of OraSure Technologies from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Monday, May 13th. StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Finally, Evercore ISI cut their target price on OraSure Technologies from $5.50 to $4.50 and set an “in-line” rating on the stock in a research note on Tuesday. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.13.

Read Our Latest Stock Analysis on OraSure Technologies

OraSure Technologies Profile

(Free Report)

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Recommended Stories

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSURFree Report).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.